Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - vTv Therapeutics Inc. | vtvt-ex322_12.htm |
| EX-32.1 - EX-32.1 - vTv Therapeutics Inc. | vtvt-ex321_7.htm |
| EX-31.2 - EX-31.2 - vTv Therapeutics Inc. | vtvt-ex312_6.htm |
| EX-31.1 - EX-31.1 - vTv Therapeutics Inc. | vtvt-ex311_8.htm |
| EX-21.1 - EX-21.1 - vTv Therapeutics Inc. | vtvt-ex211_9.htm |
| EX-10.36 - EX-10.36 - vTv Therapeutics Inc. | vtvt-ex1036_390.htm |
| EX-10.35 - EX-10.35 - vTv Therapeutics Inc. | vtvt-ex1035_391.htm |
| EX-4.3 - EX-4.3 - vTv Therapeutics Inc. | vtvt-ex43_13.htm |
| 10-K - 10-K - vTv Therapeutics Inc. | vtvt-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-8 No. 333-206335) pertaining to the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan; |
|
|
(2) |
Registration Statement (Form S-3 No. 333-223269) of vTv Therapeutics Inc.; |
|
|
(3) |
Registration Statement (Form S-3 No. 333-232571) of vTv Therapeutics Inc.; |
|
|
(4) |
Registration Statement (Form S-8 No. 333-240304) of vTv Therapeutics Inc.; and |
|
|
(5) |
Registration Statement (Form S-1 No. 333-250934) of vTv Therapeutics Inc. |
of our report dated February 20, 2020 with respect to the consolidated financial statements of vTv Therapeutics Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Raleigh, North Carolina
February 24, 2021